Combivir
Formulated to target HIV replication and indicated to support management of viral load in patients.
- Category
- HIV Management
- Active ingredients
- Lamivudine · Zidovudine
- Supply
- Rx
- Route
- Oral use
- Form
- Film-coated tablet
- Strengths
- 300/150mg
Combivir details
- Condition
- HIV Infection
- Therapeutic class
- Antiretroviral
- Pharmacological class
- NRTI
- Contraindications
- neutropaenia; severe anaemia; hypersensitivity
- Minor side effects
- nausea; headache; fatigue; diarrhoea
- Moderate side effects
- anaemia; neutropaenia; muscle pain; insomnia
- Dosage forms
- Film-coated tablet
- Administration route
- Oral use
- Supply category
- Prescription only (specially controlled medicine)
- Manufacturer
- ViiV Healthcare
- Onset Time
- 1–2 weeks
- Duration
- Ongoing maintenance
- Storage instructions
- Store below 30°C.
- Drug interactions
- Zalcitabine; Ribavirin; Stavudine
- Age restrictions
- Adjust dose for children by body weight.
Precautions and warnings
monitor liver function; regular blood monitoring for bone marrow suppression; avoid alcohol
Serious side effects
lactic acidosis, requires immediate medical attention; pancreatitis, requires immediate medical attention; peripheral neuropathy, requires immediate medical attention
Patient summary
Formulated to target HIV replication and indicated to support management of viral load in patients.
Mechanism of action
A combination of two nucleoside reverse transcriptase inhibitors that block the reverse transcriptase enzyme, preventing the HIV virus from converting its RNA into DNA, thus inhibiting viral reproduction.
Pregnancy and breastfeeding
Pregnancy: Use if benefit outweighs risk. Breastfeeding: Avoid due to HIV transmission risk.
Where this medicine is registered
- Singapore
- Hong Kong
- Thailand
- Malaysia
- Philippines
- Indonesia
- Taiwan
- South Korea
- Japan
- Australia
- New Zealand
- UAE
- South Africa
About Combivir
Combivir combines the active ingredients lamivudine and zidovudine for the management of HIV infection. Produced by ViiV Healthcare, this medication is presented as a tablet in a 300/150mg strength. The combination of these two agents is designed to assist in the sustained suppression of the virus when taken as part of a daily routine.
Combivir availability in Asia
Combivir is registered across 14 markets, including Singapore, Hong Kong and Thailand, with additional availability in Malaysia, the Philippines and Indonesia. For expats and residents across these regions, consistent access to established antiretroviral therapies is a key part of long-term health. As with all treatments for HIV infection, this medication is best used under the regular guidance and monitoring of a medical professional.